Regeneron Pharmaceuticals Inc

Change company Symbol lookup

Select an option...

REGN Regeneron Pharmaceuticals Inc

MARA Marathon Patent Group Inc

HNGR Hanger Inc

$RFTREES Refinitiv Eurozone ESG Select Index

NEMCF New Energy Metals Corp

SLCT Select Bancorp Inc

HPQ HP Inc

GOLD Barrick Gold Corp

DGNR Dragoneer Growth Opportunities Corp

EQMEF Equity Metals Corp

Go

Regeneron Pharmaceuticals Inc. (REGN) said late Tuesday that the U.S. government has agreed to buy an additional 1.25 million doses of the company's COVID-19 antibody cocktail. That would bring the U.S. supply of the cocktail, consisting of...(MarketWatch)

Regeneron Pharmaceuticals Inc. (REGN) said initial data from its Phase 1/2/3 clinical trial of its antibody cocktail in hospitalized COVID-19 patients requiring low-flow oxygen passed a futility analysis, meaning there was sufficient efficacy...(MarketWatch)

Shares of Equillium Inc. (EQ) tumbled 12.6% in premarket trading Wednesday, after the biotechnology company said it decided not to initiate a Phase 3 trial its itolizumab for the treatment of hospitalized COVID-19 patients "at this time." The...(MarketWatch)

By Ciara Linnane, MarketWatch 'Four days before a holiday with potentially the most indoor and in-person gatherings of the year in the U.S., the virus is here and more prevalent than ever,' says one analyst (MarketWatch)

Regeneron Pharmaceuticals Inc. shares (REGN) rose 1.6% in premarket trade Thursday, after the drug company blew past estimates for the third quarter and said it has shared data from its Phase 2/3 COVID-19 antibody therapy trial with regulators...(MarketWatch)

(END) Dow Jones Newswires November 05, 2020 06:36 ET (11:36 GMT) Copyright (c) 2020 Dow Jones & Company, Inc.(MarketWatch)

(END) Dow Jones Newswires November 05, 2020 06:34 ET (11:34 GMT) Copyright (c) 2020 Dow Jones & Company, Inc.(MarketWatch)

(END) Dow Jones Newswires November 05, 2020 06:34 ET (11:34 GMT) Copyright (c) 2020 Dow Jones & Company, Inc.(MarketWatch)

(END) Dow Jones Newswires November 05, 2020 06:33 ET (11:33 GMT) Copyright (c) 2020 Dow Jones & Company, Inc.(MarketWatch)

Shares of Regeneron Pharmaceuticals Inc. (REGN) slumped 1.2% in morning trading Friday, after the biotechnology company said an independent data monitoring committee (IDMC) for the REGN-COV2 antibody cocktail treatment trials for COVID-19...(MarketWatch)

(END) Dow Jones Newswires October 30, 2020 09:20 ET (13:20 GMT) Copyright (c) 2020 Dow Jones & Company, Inc.(MarketWatch)

Regeneron (REGN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.(Zacks)

Shares of Regeneron Pharmaceuticals Inc. (REGN) rose more than 3% in the extended session Wednesday after the company said its experimental antibody cocktail "significantly reduced" novel-coronavirus levels and the need for "further medical...(MarketWatch)

Regeneron Pharmaceuticals Inc. (REGN) said late Wednesday the Food and Drug Administration approved its treatment for the Ebola virus. The biotech company said the agency approved Inmazeb, the first FDA-approved treatment for Ebola. In a...(MarketWatch)

Regeneron Pharmaceuticals Inc. (REGN) said late Wednesday the Food and Drug Administration approved its treatment for the Ebola virus. The biotech company said the agency approved Inmazeb, the first FDA-approved treatment for Ebola. In a...(MarketWatch)

Shares of Eli Lilly & Co. (LLY) tumbled 3.1% in trading on Tuesday after the drug maker confirmed a data safety monitoring board had paused enrollment in a clinical study testing its experimental COVID-19 monoclonal antibody treatment in...(MarketWatch)

By Mike Murphy Leonard Schleifer tells CBS News that immunity through drug cocktail should last months, at least President Donald Trump has called the antibody cocktail he received to fend off the coronavirus "a cure...(MarketWatch)

By Mike Murphy Leonard Schleifer tells CBS News that immunity through drug cocktail should last months, at least President Donald Trump has called the antibody cocktail he received to fend off the coronavirus "a cure...(MarketWatch)

Shares of Regeneron Pharmaceuticals Inc. (REGN) were up 4.7% in premarket trading on Thursday, the day after the company said it had submitted a request for emergency authorization to the Food and Drug Administration for its experimental antibody...(MarketWatch)

By Robert Schroeder, MarketWatch President talks up Regeneron 'cocktail,' and stock rises in after-hours trading President Donald Trump said that contracting the coronavirus was a "blessing from God" in a new video released Wednesday, as he...(MarketWatch)